References
- Heshmati HM, Gharib H, van Heerden JA, Sizemore GW. Advances and controversies in the diagnosis and management of medullary thyroid carcinoma. Am J. Med.103, 60–69 (1997).
- Wells SA, Franz C. Medullary carcinoma of the thyroid gland. World J. Surgery24, 952–956 (2000).
- Lips C, Landsvater R, Hoppener J et al. Clinical screening as compared with DNA analysis in families with multiple endocrine neoplasia. N. Engl. J. Med.331, 828–835 (1994).
- Gagel RF, Cote GJ, Martins Bugalho MJ et al. Clinical use of molecular information in the management of multiple endocrine neoplasia type 2A.J. Intern Med.238, 333–341 (1995).
- Skinner MA, De Benedetti MK, Moley JF et al. Medullary thyroid carcinoma in children with multiple endocrine neoplasia type 2A and 2B. J. Pediatr Surg.1, 177–182 (1996).
- Simpson NE, Kidd KK, Goodfellow PJ et al. Assignment of multiple endocrine neoplasia type 2A to chromosome 10 by linkage. Nature6130, 528–530 (1987).
- Mathew CG, Chin KS, Easton DF et al. A linked genetic marker for multiple endocrine neoplasia type 2A on chromosome 10. Nature6130, 527–528 (1987).
- Mulligan CM, Kwok JBJ, Healey CS et al. Germline mutations of the ret proto-oncogene in multiple endocrine neoplasia type 2A. Nature363, 458–460 (1993).
- Donis-Keller H, Dou S, Chi D et al. Mutations in the ret proto-oncogene are associated with MEN 2A and FMTC. Hum. Mol. Genet.7, 851–856 (1993).
- Moley JF, Albinson C. Medullary thyroid carcinoma and the multiple endocrine neoplasia type 2 syndromes. In:Surgical Endocrinology. Doherty GM, Skogseid B (Eds.) Lippincott Williams and Wilkins, PA, USA. 541–557, (2001).
- Dralle H. Lymph node dissection and medullary thyroid carcinoma. Br. J. Surgery89, 1073–1075 (2002).
- Ukkat J, Gimm O, Brauckhoff M et al. Single center experience in primary surgery for medullary thyroid carcinoma. World J. Surgery28, 1271–1274 (2004).
- Wells SA, Skinner MA. Prophylactic thyroidectomy based on direct genetic testing in patients at risk for the multiple endocrine neoplasia type 2 syndromes. Exp. Clin. Endocrinol. Diabetes106, 29–34 (1998).
- Dralle H, Gimm O, Simon D et al. Prophylactic thyroidectomy in 75 children and adolescents with hereditary medullary thyroid carcinoma: German and Austrian experience. World J. Surgery22, 744–751 (1998).
- Mulligan LM, Eng C, Healey CS et al. Specific mutations of the RET proto-oncogene are related to disease phenotype in MEN 2A and FMTC. Nat. Genet.6, 70–74 (1994).
- Wells SA, Chi DD, Toshima K et al. Predictive DNA testing and prophylactic thyroidectomy in patients at risk for multiple endocrine neoplasia type 2A Ann. Surg.220, 237–250 (1994).
- Gongalez-Yebra B, Medrano ME, Mantilla A et al. Penetrance of inherited medullary thyroid carcinoma and genotype-phenotype correlation in a large multiple endocrine neoplasia type 2A family with C634Y RET mutation. Endocr. Pathol.14, 71–80 (2003).
- Kikumori T, Evans D, Lee J E et al. Genetic abnormalities in multiple endocrine neoplasia type 2. In: Surgical Endocrinology Doherty GM, Skogseid B (Eds.) Lippincott Williams and Wilkins, PA, USA. 531–540, (2001).
- Dackiw APB, Kuerer HM, Clark OH. Current national health insurance policies for thyroid cancer prophylactic surgery in the United States. World J. Surgery26, 903–906 (2002).
- Niederhuber J. Genetic testing for cancer: the surgeons critical role. J. Am Coll. Surg188, 74–93 (1999).